Regeneron Pharmaceuticals Inc. shares are headed for their biggest monthly drop since mid-2022 after a legal setback that ...

Regeneron Pharmaceuticals Inc. shares are headed for their biggest monthly drop since mid-2022 after a legal setback that ...

BAYRY moves ahead with the submission of an application seeking approval of darolutamide in combination with androgen ...

Dupixent is the first biologic medicine approved in the U.S. for the common lung condition, though competitors from GSK, AstraZeneca and Roche could follow.

BioAge Labs stock rose Thursday on the company's upsized IPO — reflecting enthusiasm for its approach to obesity treatments.

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing ...

Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on ...

The stock market rally extended its advance, with the S&P 500 hitting record highs, fueled by Micron and Chinese stimulus.

Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) ...

The global Age-related Macular Degeneration drugs market is set to grow from USD 10.46 billion in 2024 to USD 17.37 billion ...

New York City Mayor Eric Adams on Friday entered the courtroom where he will face federal charges of accepting bribes and illegal campaign contributions from Turkish nationals, as the Democrat ...

Shigeru Ishiba, a former defense minister known for his plainspoken opinions, will replace Fumio Kishida next week. By Motoko Rich and Hisako Ueno A whirlwind week of top-level meetings failed ...